Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response Clinical Trial

Official title: Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients

Status Terminated

Clinical Trial Summary

A rationally designed combination of adoptive T cell therapy and ipilimumab could strongly increase the proportion of CR patients, as well as the durability of response, as compared to ipilimumab or TIL alone. The investigators hypothesize that the combination of those two important modalities could result in a durable (≥ 1 year) complete response rate of 30% in stage IV melanoma patients.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response

• NCT number: NCT01988077
• Study type: Interventional
• Source: Sheba Medical Center
• Status: Terminated
• Phase: Phase 2
• Start date: October 2013
• Completion date: October 25, 2018